CN Bio declares dispatch of medication digestion and wellbeing poisonousness testing administrations

Overview

• Post By : Kumar Jeetendra


• Source: CN Bio


• Date: 31 Oct,2020

Liver toxicity is a principal safety concern during drug discovery and development, with the potential to terminate expensive clinical trials already underway. The new services will incorporate the Company’s advanced Liver-on-Chip technology and experience in the field to enable researchers to create predictive and human-relevant data, improving the translatability from discovery to clinic, and hastening new drugs to market.

CN Bio’s in vitro 3D Liver-on-Chip versions are cultured with the PhysioMimix™ microphysiological system
Based on the success of CN Bio’s Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Fee-For-Service offerings, the new toxicity testing services also provide researchers with additional bandwidth and support throughout the COVID-19 pandemic, when laboratories aren’t at full capacity. Similarly to the NAFLD/NASH Fee-For-Service, all studies use the Company’s PhysioMimix™ Organ-on-Chip system and in vitro 3D Liver-on-Chip model; replicating the mechanical and physiological microenvironment of the liver to fast-track lead targets and generate actionable data in weeks that is reproducible, and cost-effective versus animal studies.

CN Bio’s extended portfolio of solutions provides solutions to many existing workflow challenges such as: drug metabolism testing, to study the human metabolism of lead candidates, identify metabolites and correlation with mobile health – even for non clearance compounds, and security toxicity testing, to present comprehensive analysis of acute or chronic drug-induced liver damage with a wide assortment of endpoints to determine causality and mechanism of toxicity. The Company also provides complimentary service capabilities to support industry and biotechnology organisations which were affected by the COVID-19 pandemic.

One in ten drugs successfully reach clinical trials, with safety concerns being the principal cause for subsequent failure. Through our enhanced drug metabolism and safety toxicity testing services, we enable scientists to take a step beyond what is currently possible with 2D cell culture and animal studies to improve their chances of clinical success. Our technologies are on the cutting-edge of research to simulate human biological conditions, in vitro, and we are confident in our ability to support customers in developing tomorrow’s medicines, especially at this challenging time.”-Dr David Hughes, CEO, CN Bio